Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Drug: MK0974 tablet
- Registration Number
- NCT00966030
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will demonstrate the definitive bioequivalence of a solid dose formulation of MK0974 to the liquid filled capsule formulation of MK0974.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Subject is in good health
- Subject is a nonsmoker
- Subject is willing to comply with the study restrictions
Read More
Exclusion Criteria
- Subject has history of stroke, chronic seizures, or any major neurological disorder
- Subject has a history of cancer
- Subject is a nursing mother
- Subject has uncontrolled high blood pressure
- Subject has or has a history of any disease or condition that might made participation in the study unsafe or confound the study results
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 MK0974 tablet MK0974 Tablet
- Primary Outcome Measures
Name Time Method Area under the curve (AUC(0 to infinity)) following single dose administration of MK0974 tablet formulation and MK0974 liquid filled capsule formulation Through 48 Hours Post Dose Peak plasma concentration (Cmax) following single dose administration of MK0974 tablet formulation and MK0974 liquid filled capsule formulation Through 48 Hours Post Dose
- Secondary Outcome Measures
Name Time Method